Liberty Specialty Markets has launched a life sciences product that “deliberately avoids exclusions”.

The insurer says its Remedy for Life Sciences offering is built to align with the fast-growing sector’s needs.

The Asia-Pacific life sciences sector was valued at $US17.51 billion ($25.1 billion) in 2024 and is projected to reach $US54 billion ($77.43 billion) by 2034.

“We’ve deliberately avoided exclusions, and simplified policy language so it’s easier for brokers and clients to understand what they’re buying,” Asia-Pacific head of casualty specialties Alan Thorn said.

“The life sciences sector is a tight market, with constrained options and limited capacity. Liberty Remedy addresses that gap by offering purpose-built coverage that’s broader and clearer, and backed by deep technical expertise. This is about giving the market genuine choice.”

The product is designed for Asia-Pacific clients, including international exposures.